Stephen Bresnick, MD
Plastic Surgery · Encino, CANPI 1831292275
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $101,456 of the $103,780 with a category attached, or 97.8%. Sientra, Inc. accounts for 98.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $101,621 and has fallen 99.9% since, to $142 in 2025. Among plastic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $1596.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sientra, Inc.$102K
- Mentor Worldwide LLC$887
- Merz North America, Inc.$389
- Tepha Inc$224
- Revance Therapeutics, Inc.$175
- Bard Peripheral Vascular, Inc.$168
- plus $210 from 3 others
What the payments were for
- Consulting fees$101,45698%
- Speaking & faculty fees$10%
- Food & beverage$2,3232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sientra, Inc. | 15 | $101,727 |
| Mentor Worldwide LLC | 31 | $887 |
| Merz North America, Inc. | 3 | $389 |
| Tepha Inc | 3 | $224 |
| Revance Therapeutics, Inc. | 4 | $175 |
| Bard Peripheral Vascular, Inc. | 3 | $168 |
| Galderma Laboratories, L.p. | 2 | $119 |
| AbbVie | 3 | $73 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,780 in reported general payments places this provider in the 95th percentile of 780 plastic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonidine | 14 | $449 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $185 |
| Cephalexin | 29 | $177 |
| Montelukast Sodium | 26 | $154 |
| ValacyclovirValacyclovir Hcl | 17 | $120 |
| Mupirocin | 20 | $97 |
| Alprazolam | 17 | $48 |
| Ondansetron OdtOndansetron | 16 | $47 |
Paid to pharmacies, not to this prescriber.
Other plastic surgery in Encino
- Rahm NazeraliPalo Alto$1.5M
- Vipul DevBakersfield$1.1M
- Arash MomeniPalo Alto$836K
- Anne PeledSan Francisco$570K
- Salvatore PacellaSan Diego$517K
- Hani SbitanySan Francisco$510K
- John ApostolidesSan Diego$460K
- Garrett WirthNewport Beach$362K
- Michael BainNewport Beach$341K
- Joshua KormanMountain View$335K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.